Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: OBT076, a CD205-directed antibody-drug conjugate
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Oxford BioTherapeutics Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT04064359
- Locations
- 🇺🇸
The State University of Iowa, Iowa City, Iowa, United States
🇺🇸St. Elizabeth Healthcare, Edgewood, Kentucky, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
© Copyright 2025. All Rights Reserved by MedPath